Results 41 to 50 of about 8,326 (241)

Cardioprotective action of aprepitant in a rat model of ischemia-reperfusioninduced myocardial injury: role of PI3K-AkT-GSK-3β-HIF-1α signaling pathway

Acta Cirúrgica Brasileira, 2022
Purpose: The present study explored the role and mechanism involved in aprepitant-induced cardioprotective effects in rat model of ischemia-reperfusion injury.
Mei Qian, Yang Liu
doaj   +1 more source

Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting [PDF]

, 2016
BACKGROUND We examined the efficacy of olanzapine for the prevention of nausea and vomiting in patients receiving highly emetogenic chemotherapy.
Bajaj, Madhuri, Biggs, David, Dietrich, Leah, Lafky, Jacqueline M., Liu, Heshan, Loprinzi, Charles L., Navari, Rudolph M., Powell, Steven F., Qin, Rui, Ruddy, Kathryn J.   +9 more
core   +1 more source

The combined use of imaging approaches to assess drug release from multicomponent solid dispersions [PDF]

, 2016
PURPOSE: Imaging methods were used as tools to provide an understanding of phenomena that occur during dissolution experiments, and ultimately to select the best ratio of two polymers in a matrix in terms of enhancement of the dissolution rate and ...
Beránek, J, Ewing, AV, Gajdošová, M, Kazarian, SG, Pekárek, T, Punčochová, K, Štěpánek, F   +6 more
core   +1 more source

Consensus recommendations for the prevention of vomiting and nausea following high-emetic-risk chemotherapy [PDF]

, 2010
In this update of our 2005 document, we used an evidence-based approach whenever possible to formulate recommendations, emphasizing the results of controlled trials concerning the best use of antiemetic agents for the prevention of emesis and nausea ...
Ballatori, Enzo, Bria, Emilio, Einhorn, Lawrence H, Espersen, Birgitte, Grunberg, Steven, Herrstedt, Jørn, Hesketh, Paul, Kris, Mark G, Morrow, Gary, Rittenberg, Cynthia, Saito, Mitsue, Tonato, Maurizio   +11 more
core   +1 more source

Neurokinin-1 inhibitors in the prevention of nausea and vomiting from highly emetogenic chemotherapy: a network meta-analysis

Therapeutic Advances in Medical Oncology, 2016
A network meta-analysis of the comparative effectiveness of neurokinin 1 (NK-1) inhibitors in the prophylaxis of highly emetogenic chemotherapy induced nausea and vomiting has been conducted.
Omar Abdel-Rahman
doaj   +1 more source

Need for Flexible Adjustment of the Treatment Schedule for Aprepitant Administration against Erlotinib-Induced Refractory Pruritus and Skin Rush

Case Reports in Oncology, 2019
Common dermatological side-effects associated with erlotinib, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), include pruritus and skin rash, which are mediated by substance P, leading to the occasional discontinuation of cancer ...
Nobuhiko Seki, Ryosuke Ochiai, Terunobu Haruyama, Masashi Ishihara, Maika Natsume, Yoko Fukasawa, Takahiko Sakamoto, Shigeru Tanzawa, Ryo Usui, Takeshi Honda, Shuji Ota, Yasuko Ichikawa, Kiyotaka Watanabe   +12 more
doaj   +1 more source

Phase II study of fosaprepitant + 5HT3 receptor antagonist + dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: A Hoosier Cancer Research Network Study [PDF]

, 2016
Purpose A phase III study adding aprepitant to a 5HT3 receptor antagonist (5HT3-RA) plus dexamethasone in germ cell tumor (GCT) patients treated with 5-day cisplatin combination chemotherapy demonstrated a significant improvement in complete response (
Adra, Nabil, Albany, Costantine, Brames, Mary J., Breen, Timothy, Calley, Cynthia, Case-Eads, Somer, Einhorn, Lawrence H., Fausel, Christopher A., Hanna, Nasser H., Hauke, Ralph J., Liu, Ziyue, Picus, Joel   +11 more
core   +2 more sources

Evaluating Aprepitant single-dose plus granisetron and dexamethasone in children receiving highly emetogenic chemotherapy for the prevention of chemotherapy-induced nausea and vomiting: A triple-blinded randomized clinical trial

Hematology, Transfusion and Cell Therapy, 2023
Introduction: This study was performed to evaluate the degree of 3-day chemotherapy-induced nausea and vomiting (CINV) in children with cancer who received highly emetogenic chemotherapy (HEC) to ascertain the efficacy of aprepitant single-dose on dayL 1
Aziz Eghbali, Fatemeh Khazaei Kohpar, Kazem Ghaffari, Roghayeh Rahimi Afzal, Aygin Eghbali, Ali Ghasemi   +5 more
doaj   +1 more source

Stability of Aprepitant Injectable Emulsion in Alternate Infusion Bags, in Refrigerated Storage, and Admixed with Dexamethasone and Palonosetron

Drug Design, Development and Therapy, 2021
Thomas Ottoboni, 1 Laura Lerner, 1 Arlene Santhouse 2 1Pharmaceutical and Translational Science, Heron Therapeutics, Inc, San Diego, CA, USA; 2Medical Affairs, Heron Therapeutics, Inc, San Diego, CA, USACorrespondence: Thomas OttoboniPharmaceutical and
Ottoboni T, Lerner L, Santhouse A
doaj  

NEPA, a new fixed combination of netupitant and palonosetron, is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in the UK [PDF]

, 2017
Background: The objective was to evaluate the cost-effectiveness of NEPA, an oral fixed combination netupitant (NETU, 300 mg) and palonosetron (PA, 0.5 mg) compared with aprepitant and palonosetron (APPA) or palonosetron (PA) alone, to prevent ...
Bourhis, Francois, Cawston, Helene, Di'Agostino, Paolo, Eriksson, Jennifer, McGuire, Alistair, Ruffo, Pierfrancesco, Schwartzberg, Lee, Turini, Marco   +7 more
core   +2 more sources